Results from expanded access programs: a review of academic literature 155 7♦ Comparison with other data When comparing the expanded access program with clinical trials, the authors conclude that: ‘Despite the limited number of patients included in this retrospective analysis, exceptionally long response durations were observed with venetoclax monotherapy in pretreated sAML in comparison to previous studies.’ Conclusion The authors conclude that: ‘Venetoclax monotherapy is safe and is able to induce durable responses in elderly patients with secondary AML after treatment failure with HMA.’ ‘Responses were clinically apparent within 4-6 weeks, favoring a short trial of venetoclax in patients without standard options. High baseline BCL-2 and/or BIM expression may identify responders to venetoclax treatment.’ The authors suggest the conduct of future studies: ‘These findings should be validated in future clinical trials.’
RkJQdWJsaXNoZXIy MTk4NDMw